FDA says BioMarin drug results in "modest" improvements

|About: BioMarin Pharmaceutical Inc. (BMRN)|By:, SA News Editor

BioMarin (BMRN +8.3%) has put together a strong session after starting the day only slightly higher.

Available now are the briefing docs for next week's Vimizim Ad Com.

FDA staff characterizes the benefit conferred on Morquio A patients as "modest."

Full documents